Drug,Chemical Structure,Adverse Effect / Toxicity,Species,Dose,Dose Type,Route,Source,Source Link,Year,no_stereoisomer
Acalabrutinib,CC#CC(=O)N1CCC[C@H]1C1=NC(C2=CC=C(C=C2)C(=O)NC2=NC=CC=C2)=C2N1C=CN=C2N,Hepatobiliary disorders,Human,-1.4471580313422192,Repeated,Oral,"FDA approval package document: Approval Package 210259/S-000 Part 07, page:13 PDF 479k",https://www.pharmapendium.com/browse/fda/Acalabrutinib/790d7b2ca966a263cae6a013477587ca?reference=13,2017.0,CC#CC(=O)N1CCC[CH]1C1=NC(C2=CC=C(C=C2)C(=O)NC2=NC=CC=C2)=C2N1C=CN=C2N
Ambrisentan,COC([C@H](OC1=NC(C)=CC(C)=N1)C(O)=O)(C1=CC=CC=C1)C1=CC=CC=C1,Hepatobiliary disorders,Human,-1.0,Repeated,Oral,"FDA approval package document: Approval Package 022081/S-017 Part 05, page:53 PDF 6131k",https://www.pharmapendium.com/browse/fda/Ambrisentan/7eb36e2aef104a107f4e978fef0262de?reference=53,2011.0,COC([CH](OC1=NC(C)=CC(C)=N1)C(O)=O)(C1=CC=CC=C1)C1=CC=CC=C1
Anidulafungin,CCCCCOC1=CC=C(C=C1)C1=CC=C(C=C1)C1=CC=C(C=C1)C(=O)N[C@H]1C[C@@H](O)[C@@H](O)NC(=O)[C@@H]2[C@@H](O)[C@@H](C)CN2C(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H]2C[C@@H](O)CN2C(=O)[C@@H](NC1=O)[C@@H](C)O)[C@H](O)[C@@H](O)C1=CC=C(O)C=C1)[C@@H](C)O,Hepatobiliary disorders,Human,-0.6989700043360189,Repeated,Intravenous,"EMA approval document: Assessment Report EMA/916359/2019; EMEA/H/C/000788/P46/046, page:29 PDF 1307k",https://www.pharmapendium.com/browse/ema/Anidulafungin/8db8b31deadd98115829b6333f16e5f2?reference=29,2018.0,CCCCCOC1=CC=C(C=C1)C1=CC=C(C=C1)C1=CC=C(C=C1)C(=O)N[CH]1C[CH](O)[CH](O)NC(=O)[CH]2[CH](O)[CH](C)CN2C(=O)[CH](NC(=O)[CH](NC(=O)[CH]2C[CH](O)CN2C(=O)[CH](NC1=O)[CH](C)O)[CH](O)[CH](O)C1=CC=C(O)C=C1)[CH](C)O
Aripiprazole,ClC1=CC=CC(N2CCN(CCCCOC3=CC=C4CCC(=O)NC4=C3)CC2)=C1Cl,Hepatobiliary disorders,Human,-1.4771212547196624,Repeated,Oral,"FDA approval package document: Approval Package 021436/S-019, S-020, S-022; 021713/S-014 Part 05, page:28 PDF 4582k",https://www.pharmapendium.com/browse/fda/Aripiprazole/9fd1fb67d42642b109846933541b098f?reference=28,2008.0,ClC1=CC=CC(N2CCN(CCCCOC3=CC=C4CCC(=O)NC4=C3)CC2)=C1Cl
Avapritinib,CN1C=C(C=N1)C1=CN2N=CN=C(N3CCN(CC3)C3=NC=C(C=N3)[C@@](C)(N)C3=CC=C(F)C=C3)C2=C1,Hepatobiliary disorders,Human,-2.7781512503836434,Repeated,Oral,"FDA approval package document: Approval Package 212608/S-000 Part 05, page:30 PDF 757k",https://www.pharmapendium.com/browse/fda/Avapritinib/464e25d0cd7b6ae46c5d8ad3184c38de?reference=30,2020.0,CN1C=C(C=N1)C1=CN2N=CN=C(N3CCN(CC3)C3=NC=C(C=N3)[C](C)(N)C3=CC=C(F)C=C3)C2=C1
Bempedoic Acid,CC(C)(CCCCCC(O)CCCCCC(C)(C)C(O)=O)C(O)=O,Hepatobiliary disorders,Human,-2.255272505103306,Repeated,Oral,"EMA approval document: Public Assessment Report EMA/CHMP/86202/2020; EMEA/H/C/004958/0000, page:127 PDF 2756k",https://www.pharmapendium.com/browse/ema/Bempedoic Acid/e2ef502ac064d1e1c9910b26ad1d2c8f?reference=127,2020.0,CC(C)(CCCCCC(O)CCCCCC(C)(C)C(O)=O)C(O)=O
Boceprevir,[H][C@]12CN([C@H](C(=O)NC(CC3CCC3)C(=O)C(N)=O)[C@@]1([H])C2(C)C)C(=O)[C@@H](NC(=O)NC(C)(C)C)C(C)(C)C,Hepatobiliary disorders,Human,-3.380211241711606,Repeated,Oral,"EMA approval document: ANNEX I, page:13 PDF 428k",https://www.pharmapendium.com/browse/ema/Boceprevir/3eded3dcf36e4c3ebdde3f8dd5fdd6aa?reference=13,2012.0,[H][C]12CN([CH](C(=O)NC(CC3CCC3)C(=O)C(N)=O)[C]1([H])C2(C)C)C(=O)[CH](NC(=O)NC(C)(C)C)C(C)(C)C
Brexpiprazole,O=C1NC2=CC(OCCCCN3CCN(CC3)C3=C4C=CSC4=CC=C3)=CC=C2C=C1,Hepatobiliary disorders,Human,-0.6020599913279624,Repeated,Oral,"FDA approval package document: Medical/Clinical Review 205422/S-000 Part 04, page:93 PDF 20059k",https://www.pharmapendium.com/browse/fda/Brexpiprazole/00ccb22ace460844be09f496a697ac0d?reference=93,2014.0,O=C1NC2=CC(OCCCCN3CCN(CC3)C3=C4C=CSC4=CC=C3)=CC=C2C=C1
Budesonide,[H][C@@]12C[C@@]3([H])[C@]4([H])CCC5=CC(=O)C=C[C@]5(C)[C@@]4([H])[C@@H](O)C[C@]3(C)[C@@]1(OC(CCC)O2)C(=O)CO,Hepatobiliary disorders,Human,-0.9542425094393249,Repeated,Oral,"FDA approval package document: Medical/Clinical Review 203634/S-000 Part 08, page:6 PDF 1084k",https://www.pharmapendium.com/browse/fda/Budesonide/dc986efb87dae54ab8dad77e712e1898?reference=6,2011.0,[H][C]12C[C]3([H])[C]4([H])CCC5=CC(=O)C=C[C]5(C)[C]4([H])[CH](O)C[C]3(C)[C]1(OC(CCC)O2)C(=O)CO
Buprenorphine,[H][C@@]1(C[C@]23CC[C@@]1(OC)[C@@H]1OC4=C(O)C=CC5=C4[C@]21CCN(CC1CC1)[C@@H]3C5)[C@](C)(O)C(C)(C)C,Hepatobiliary disorders,Human,-1.3010299956639813,Repeated,Skin,"FDA approval package document: Medical/Clinical Review 021306/S-000 Part 09, page:2 PDF 481k",https://www.pharmapendium.com/browse/fda/Buprenorphine/ac81c148b75e5c4579ff9b5361c2a308?reference=2,2010.0,[H][C]1(C[C]23CC[C]1(OC)[CH]1OC4=C(O)C=CC5=C4[C]21CCN(CC1CC1)[CH]3C5)[C](C)(O)C(C)(C)C
Cabotegravir Sodium,[H][C@@]12CN3C=C(C(=O)NCC4=C(F)C=C(F)C=C4)C(=O)C([O-])=C3C(=O)N1[C@@H](C)CO2,Hepatobiliary disorders,Human,-2.6020599913279625,Repeated,Intramuscular,"FDA approval package document: Review 212887/S-000; 212888/S-000 Part 18, page:17 PDF 1560k",https://www.pharmapendium.com/browse/fda/Cabotegravir Sodium/be955c24495f457e89987c3a768ca01f?reference=17,2019.0,[H][C]12CN3C=C(C(=O)NCC4=C(F)C=C(F)C=C4)C(=O)C([O-])=C3C(=O)N1[CH](C)CO2
Cladribine,NC1=NC(Cl)=NC2=C1N=CN2[C@@H]1C[C@H](O)[C@@H](CO)O1,Hepatobiliary disorders,Human,-1.3979400086720377,Repeated,Oral,"FDA approval package document: Medical/Clinical Review 022561/S-000 Part 11, page:160 PDF 23631k",https://www.pharmapendium.com/browse/fda/Cladribine/cdf7c590901bed412a0ba7bd776ef517?reference=160,2010.0,NC1=NC(Cl)=NC2=C1N=CN2[CH]1C[CH](O)[CH](CO)O1
Cobicistat,CC(C)C1=NC(CN(C)C(=O)N[C@@H](CCN2CCOCC2)C(=O)N[C@H](CC[C@H](CC2=CC=CC=C2)NC(=O)OCC2=CN=CS2)CC2=CC=CC=C2)=CS1,Hepatobiliary disorders,Human,-2.1760912590556813,Repeated,Oral,"EMA approval document: Assessment Report EMA/CHMP/609914/2013; EMEA/H/C/002572/0000, page:63 PDF 1120k",https://www.pharmapendium.com/browse/ema/Cobicistat/0b17670219c561c8ad7f563892377dc6?reference=63,2013.0,CC(C)C1=NC(CN(C)C(=O)N[CH](CCN2CCOCC2)C(=O)N[CH](CC[CH](CC2=CC=CC=C2)NC(=O)OCC2=CN=CS2)CC2=CC=CC=C2)=CS1
Copanlisib Dihydrochloride,COC1=C2N=C(NC(=O)C3=CN=C(N)N=C3)N3CCN=C3C2=CC=C1OCCCN1CCOCC1,Hepatobiliary disorders,Human,-1.4471580313422192,Repeated,Intravenous,"FDA approval package document: Approval Package 209936/S-000 Part 02, page:84 PDF 11850k",https://www.pharmapendium.com/browse/fda/Copanlisib Dihydrochloride/3a7a918dba0779ad831f58c4b35fbbbb?reference=84,2017.0,COC1=C2N=C(NC(=O)C3=CN=C(N)N=C3)N3CCN=C3C2=CC=C1OCCCN1CCOCC1
Deferasirox,OC(=O)C1=CC=C(C=C1)N1N=C(N=C1C1=CC=CC=C1O)C1=CC=CC=C1O,Hepatobiliary disorders,Human,-1.1760912590556813,Repeated,Oral,"FDA approval package document: Medical/Clinical Review 021882/S-015, page:78 PDF 19012k",https://www.pharmapendium.com/browse/fda/Deferasirox/1bc5e6d94c09702cdc491a7390df0456?reference=78,2013.0,OC(=O)C1=CC=C(C=C1)N1N=C(N=C1C1=CC=CC=C1O)C1=CC=CC=C1O
Deferiprone,CN1C=CC(=O)C(O)=C1C,Hepatobiliary disorders,Human,-1.8750612633917,Repeated,Oral,"FDA approval package document: Medical/Clinical Review 021825/S-000 Part 05, page:13 PDF 3049k",https://www.pharmapendium.com/browse/fda/Deferiprone/854bdd01efb0b088e3fe28b227c9037b?reference=13,2011.0,CN1C=CC(=O)C(O)=C1C
Delamanid,C[C@]1(COC2=CC=C(C=C2)N2CCC(CC2)OC2=CC=C(OC(F)(F)F)C=C2)CN2C=C(N=C2O1)N(=O)=O,Hepatobiliary disorders,Human,-2.0,Repeated,Oral,"EMA approval document: Assessment Report EMA/526836/2020; EMEA/H/C/002552/II/0040, page:60 PDF 2915k",https://www.pharmapendium.com/browse/ema/Delamanid/200536e9de9194f396f60127006f480f?reference=60,2020.0,C[C]1(COC2=CC=C(C=C2)N2CCC(CC2)OC2=CC=C(OC(F)(F)F)C=C2)CN2C=C(N=C2O1)N(=O)=O
Dronedarone Hydrochloride,CCCCN(CCCC)CCCOC1=CC=C(C=C1)C(=O)C1=C(CCCC)OC2=CC=C(NS(C)(=O)=O)C=C12,Hepatobiliary disorders,Human,-2.9030899869919438,Repeated,Intramuscular,"EMA approval document: Assessment Report EMEA/H/C/1043/A20/005, page:18 PDF 943k",https://www.pharmapendium.com/browse/ema/Dronedarone Hydrochloride/ac8f06b056b2958a2f0f1a402458ce78?reference=18,2011.0,CCCCN(CCCC)CCCOC1=CC=C(C=C1)C(=O)C1=C(CCCC)OC2=CC=C(NS(C)(=O)=O)C=C12
Efavirenz,FC(F)(F)[C@]1(OC(=O)NC2=CC=C(Cl)C=C12)C#CC1CC1,Hepatobiliary disorders,Human,-2.7781512503836434,Repeated,Oral,"EMA approval document: Assessment Report EMA/260283/2015; EMEA/H/C/000249/II/0126/G, page:55 PDF 2525k",https://www.pharmapendium.com/browse/ema/Efavirenz/c3645ccb445cfadf4554092a3dd66f73?reference=55,2015.0,FC(F)(F)[C]1(OC(=O)NC2=CC=C(Cl)C=C12)C#CC1CC1
Empagliflozin,OC[C@H]1O[C@H]([C@H](O)[C@@H](O)[C@@H]1O)C1=CC(CC2=CC=C(O[C@H]3CCOC3)C=C2)=C(Cl)C=C1,Hepatobiliary disorders,Human,-1.3979400086720377,Repeated,Oral,"FDA approval package document: Approval Package 204629/S-008 Part 19, page:7 PDF 1072k",https://www.pharmapendium.com/browse/fda/Empagliflozin/1b4c803f697adbcc050fcd207860290f?reference=7,2015.0,OC[CH]1O[CH]([CH](O)[CH](O)[CH]1O)C1=CC(CC2=CC=C(O[CH]3CCOC3)C=C2)=C(Cl)C=C1
Encorafenib,COC(=O)N[C@@H](C)CNC1=NC=CC(=N1)C1=CN(N=C1C1=C(F)C(NS(C)(=O)=O)=CC(Cl)=C1)C(C)C,Hepatobiliary disorders,Human,-2.4771212547196626,Repeated,Oral,"FDA approval package document: Cross Discipline Team Leader Review 210496/S-000 Part 07, page:20 PDF 2018k",https://www.pharmapendium.com/browse/fda/Encorafenib/e66d307c7190a375b0fc161a0653461c?reference=20,2018.0,COC(=O)N[CH](C)CNC1=NC=CC(=N1)C1=CN(N=C1C1=C(F)C(NS(C)(=O)=O)=CC(Cl)=C1)C(C)C
Entrectinib,CN1CCN(CC1)C1=CC=C(C(=O)NC2=NNC3=C2C=C(CC2=CC(F)=CC(F)=C2)C=C3)C(NC2CCOCC2)=C1,Hepatobiliary disorders,Human,-2.7781512503836434,Repeated,Oral,"EMA approval document: Public Assessment Report EMA/379739/2020; EMEA/H/C/004936/0000, page:174 PDF 8453k",https://www.pharmapendium.com/browse/ema/Entrectinib/9332dd773f57f5b7f9ce0ceb56ae2bef?reference=174,2020.0,CN1CCN(CC1)C1=CC=C(C(=O)NC2=NNC3=C2C=C(CC2=CC(F)=CC(F)=C2)C=C3)C(NC2CCOCC2)=C1
Eslicarbazepine Acetate,CC(=O)O[C@H]1CC2=C(C=CC=C2)N(C(N)=O)C2=C1C=CC=C2,Hepatobiliary disorders,Human,-3.0791812460476247,Repeated,Oral,"FDA approval package document: Medical/Clinical Review 022416/S-000 Part 20, page:6 PDF 979k",https://www.pharmapendium.com/browse/fda/Eslicarbazepine Acetate/90891ca1812206a2e54e32e80cd3dfd1?reference=6,2013.0,CC(=O)O[CH]1CC2=C(C=CC=C2)N(C(N)=O)C2=C1C=CC=C2
Everolimus,CO[C@@H]1C[C@@H](CC[C@H]1OCCO)C[C@@H](C)[C@@H]1CC(=O)[C@H](C)\C=C(C)\[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)\C=C\C=C\C=C(C)\[C@H](C[C@@H]2CC[C@@H](C)[C@@](O)(O2)C(=O)C(=O)N2CCCC[C@H]2C(=O)O1)OC,Hepatobiliary disorders,Human,-1.0,Repeated,Oral,"FDA approval package document: Approval Package 022334/S-016 Part 05, page:23 PDF 429k",https://www.pharmapendium.com/browse/fda/Everolimus/1c322d0fc6dd54b59b6b934c8326897c?reference=23,2012.0,CO[CH]1C[CH](CC[CH]1OCCO)C[CH](C)[CH]1CC(=O)[CH](C)\C=C(C)\[CH](O)[CH](OC)C(=O)[CH](C)C[CH](C)\C=C\C=C\C=C(C)\[CH](C[CH]2CC[CH](C)[C](O)(O2)C(=O)C(=O)N2CCCC[CH]2C(=O)O1)OC
Fentanyl,CCC(=O)N(C1CCN(CC1)CCC1=CC=CC=C1)C1=CC=CC=C1,Hepatobiliary disorders,Human,-0.6020599913279624,Repeated,Sublingual,"FDA approval package document: Medical/Clinical Review 202788/S-000 Part 06, page:36 PDF 5525k",https://www.pharmapendium.com/browse/fda/Fentanyl/76d14c87c7a21c7cc63492cba5614420?reference=36,2011.0,CCC(=O)N(C1CCN(CC1)CCC1=CC=CC=C1)C1=CC=CC=C1
Fidaxomicin,[H][C@]1(C\C=C(C)\C=C(C)\[C@H](O[C@]2([H])OC(C)(C)[C@@H](OC(=O)C(C)C)[C@H](O)[C@@H]2O)[C@@H](CC)\C=C(C)\[C@@H](O)C\C=C\C=C(CO[C@@H]2O[C@H](C)[C@@H](OC(=O)C3=C(O)C(Cl)=C(O)C(Cl)=C3CC)[C@H](O)[C@@H]2OC)\C(=O)O1)[C@@H](C)O,Hepatobiliary disorders,Human,-2.6020599913279625,Repeated,Oral,"EMA approval document: Assessment Report EMA/857570/2011; EMEA/H/C/2087, page:65 PDF 966k",https://www.pharmapendium.com/browse/ema/Fidaxomicin/0ddc1ba8cfbbbb4f77b87c8f806ab0ef?reference=65,2011.0,[H][C]1(C\C=C(C)\C=C(C)\[CH](O[C]2([H])OC(C)(C)[CH](OC(=O)C(C)C)[CH](O)[CH]2O)[CH](CC)\C=C(C)\[CH](O)C\C=C\C=C(CO[CH]2O[CH](C)[CH](OC(=O)C3=C(O)C(Cl)=C(O)C(Cl)=C3CC)[CH](O)[CH]2OC)\C(=O)O1)[CH](C)O
Fingolimod Hydrochloride,CCCCCCCCC1=CC=C(CCC(N)(CO)CO)C=C1,Hepatobiliary disorders,Human,-1.3979400086720377,Repeated,Oral,"FDA approval package document: Medical/Clinical Review 022527/S-000 Part 09, page:11 PDF 398k",https://www.pharmapendium.com/browse/fda/Fingolimod Hydrochloride/9bb72c61d342b78ade7e913cd0f3dd3c?reference=11,2009.0,CCCCCCCCC1=CC=C(CCC(N)(CO)CO)C=C1
Glycopyrrolate,C[N+]1(C)CCC(C1)OC(=O)C(O)(C1CCCC1)C1=CC=CC=C1,Hepatobiliary disorders,Human,-1.6989700043360187,Repeated,Inhalation,"FDA approval package document: Medical/Clinical Review 208437/S-000 Part 05, page:16 PDF 677k",https://www.pharmapendium.com/browse/fda/Glycopyrrolate/3e837b9c14e41cecba0bc8ae8ba6c98f?reference=16,2016.0,C[N+]1(C)CCC(C1)OC(=O)C(O)(C1CCCC1)C1=CC=CC=C1
Ibrutinib,NC1=C2C(=NC=N1)N(N=C2C1=CC=C(OC2=CC=CC=C2)C=C1)[C@@H]1CCCN(C1)C(=O)C=C,Hepatobiliary disorders,Human,-2.6232492903979003,Repeated,Oral,"EMA approval document: Assessment Report EMA/373867/2016; EMEA/H/C/003791/II/0016, page:55 PDF 4989k",https://www.pharmapendium.com/browse/ema/Ibrutinib/1ae8299578a99071602d1f71990059f4?reference=55,2016.0,NC1=C2C(=NC=N1)N(N=C2C1=CC=C(OC2=CC=CC=C2)C=C1)[CH]1CCCN(C1)C(=O)C=C
Ivacaftor,CC(C)(C)C1=CC(=C(O)C=C1NC(=O)C1=CNC2=CC=CC=C2C1=O)C(C)(C)C,Hepatobiliary disorders,Human,-1.0791812460476249,Repeated,Oral,"FDA approval package document: Medical/Clinical Review 203188/S-000 Part 06, page:18 PDF 3676k",https://www.pharmapendium.com/browse/fda/Ivacaftor/dea42faf9d55aef501f243c607521f57?reference=18,2011.0,CC(C)(C)C1=CC(=C(O)C=C1NC(=O)C1=CNC2=CC=CC=C2C1=O)C(C)(C)C
Lacosamide,COC[C@@H](NC(C)=O)C(=O)NCC1=CC=CC=C1,Hepatobiliary disorders,Human,-2.7781512503836434,Repeated,Oral,"FDA approval package document: Medical/Clinical Review 022253/S-000; 022254/S-000 Part 03, page:92 PDF 6885k",https://www.pharmapendium.com/browse/fda/Lacosamide/e8591abb7cc398480feaf4f98f1b54e2?reference=92,2008.0,COC[CH](NC(C)=O)C(=O)NCC1=CC=CC=C1
Lamotrigine,NC1=NC(N)=C(N=N1)C1=CC=CC(Cl)=C1Cl,Hepatobiliary disorders,Human,-2.7781512503836434,Repeated,Oral,"FDA approval package document: Medical/Clinical Review 022509/S-000 Part 03, page:11 PDF 405k",https://www.pharmapendium.com/browse/fda/Lamotrigine/7a906752dd615052ec50add93b5ada30?reference=11,2009.0,NC1=NC(N)=C(N=N1)C1=CC=CC(Cl)=C1Cl
Lenalidomide,NC1=CC=CC2=C1CN(C1CCC(=O)NC1=O)C2=O,Hepatobiliary disorders,Human,-1.4471580313422192,Repeated,Oral,"EMA approval document: Assessment Report EMA/CHMP/108277/2017; EMEA/H/C/000717/II/0089/G, page:61 PDF 3010k",https://www.pharmapendium.com/browse/ema/Lenalidomide/53d7d52fce5760b22f1840ede974c260?reference=61,2017.0,NC1=CC=CC2=C1CN(C1CCC(=O)NC1=O)C2=O
Lesinurad,OC(=O)CSC1=NN=C(Br)N1C1=C2C=CC=CC2=C(C=C1)C1CC1,Hepatobiliary disorders,Human,-2.6020599913279625,Repeated,Oral,"EMA approval document: Assessment Report EMA/6459/2016; EMEA/H/C/003932/0000, page:110 PDF 5667k",https://www.pharmapendium.com/browse/ema/Lesinurad/d22d8c9f5d65c0aae620ada4cabc6eaa?reference=110,2015.0,OC(=O)CSC1=NN=C(Br)N1C1=C2C=CC=CC2=C(C=C1)C1CC1
Linagliptin,CC#CCN1C(=NC2=C1C(=O)N(CC1=NC3=CC=CC=C3C(C)=N1)C(=O)N2C)N1CCC[C@@H](N)C1,Hepatobiliary disorders,Human,-0.6989700043360189,Repeated,Oral,"FDA approval package document: Medical/Clinical Review 201280/S-000 Part 04, page:89 PDF 5485k",https://www.pharmapendium.com/browse/fda/Linagliptin/4040600348d5f8e24c3f5c858638a448?reference=89,2010.0,CC#CCN1C(=NC2=C1C(=O)N(CC1=NC3=CC=CC=C3C(C)=N1)C(=O)N2C)N1CCC[CH](N)C1
Liraglutide,CCCCCCCCCCCCCCCC(=O)N[C@@H](CCC(=O)NCCCC[C@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](CC(C)C)NC(=O)[C@H](CC1=CC=C(O)C=C1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC1=CC=CC=C1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC1=CN=CN1)[C@@H](C)O)[C@@H](C)O)C(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(=O)N[C@@H](CC1=CNC2=C1C=CC=C2)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(O)=O)C(O)=O,Hepatobiliary disorders,Human,-0.47712125471966244,Repeated,Subcutaneous,"FDA approval package document: Medical/Clinical Review 206321/S-000 Part 07, page:5 PDF 476k",https://www.pharmapendium.com/browse/fda/Liraglutide/3200929bc5c94d88e57d606e364297ae?reference=5,2014.0,CCCCCCCCCCCCCCCC(=O)N[CH](CCC(=O)NCCCC[CH](NC(=O)[CH](C)NC(=O)[CH](C)NC(=O)[CH](CCC(N)=O)NC(=O)CNC(=O)[CH](CCC(O)=O)NC(=O)[CH](CC(C)C)NC(=O)[CH](CC1=CC=C(O)C=C1)NC(=O)[CH](CO)NC(=O)[CH](CO)NC(=O)[CH](NC(=O)[CH](CC(O)=O)NC(=O)[CH](CO)NC(=O)[CH](NC(=O)[CH](CC1=CC=CC=C1)NC(=O)[CH](NC(=O)CNC(=O)[CH](CCC(O)=O)NC(=O)[CH](C)NC(=O)[CH](N)CC1=CN=CN1)[CH](C)O)[CH](C)O)C(C)C)C(=O)N[CH](CCC(O)=O)C(=O)N[CH](CC1=CC=CC=C1)C(=O)N[CH]([CH](C)CC)C(=O)N[CH](C)C(=O)N[CH](CC1=CNC2=C1C=CC=C2)C(=O)N[CH](CC(C)C)C(=O)N[CH](C(C)C)C(=O)N[CH](CCCNC(N)=N)C(=O)NCC(=O)N[CH](CCCNC(N)=N)C(=O)NCC(O)=O)C(O)=O
Lorcaserin Hydrochloride,C[C@H]1CNCCC2=CC=C(Cl)C=C12,Hepatobiliary disorders,Human,-1.0,Repeated,Oral,"FDA approval package document: Medical/Clinical Review 022529/S-000 Part 09, page:10 PDF 2134k",https://www.pharmapendium.com/browse/fda/Lorcaserin Hydrochloride/290b233d73c8c3628efb1f5e7797d526?reference=10,2012.0,C[CH]1CNCCC2=CC=C(Cl)C=C12
Maraviroc,[H][C@]12CC[C@]([H])(C[C@H](C1)N1C(C)=NN=C1C(C)C)N2CC[C@H](NC(=O)C1CCC(F)(F)CC1)C1=CC=CC=C1,Hepatobiliary disorders,Human,-2.1760912590556813,Repeated,Oral,"FDA approval package document: Medical/Clinical Review 208984/S-017 Part 02, page:11 PDF 406k",https://www.pharmapendium.com/browse/fda/Maraviroc/13a38ddf3198ad19f88ef484538c815a?reference=11,2016.0,[H][C]12CC[C]([H])(C[CH](C1)N1C(C)=NN=C1C(C)C)N2CC[CH](NC(=O)C1CCC(F)(F)CC1)C1=CC=CC=C1
Micafungin Sodium,[H][C@@]12C[C@@H](O)CN1C(=O)[C@@H](NC(=O)[C@H](C[C@@H](O)[C@@H](O)NC(=O)[C@]1([H])[C@@H](O)[C@@H](C)CN1C(=O)[C@@H](NC(=O)[C@@H](NC2=O)[C@H](O)[C@@H](O)C1=CC=C(O)C(OS([O-])(=O)=O)=C1)[C@H](O)CC(N)=O)NC(=O)C1=CC=C(C=C1)C1=NOC(=C1)C1=CC=C(OCCCCC)C=C1)[C@@H](C)O,Hepatobiliary disorders,Human,-1.0,Repeated,Intravenous,"EMA approval document: Assessment Report EMA/CHMP/804861/2015; EMEA/H/C/000734/P46/038, page:12 PDF 313k",https://www.pharmapendium.com/browse/ema/Micafungin Sodium/462949c2dcb917251daf6f4cb6602ec1?reference=12,2015.0,[H][C]12C[CH](O)CN1C(=O)[CH](NC(=O)[CH](C[CH](O)[CH](O)NC(=O)[C]1([H])[CH](O)[CH](C)CN1C(=O)[CH](NC(=O)[CH](NC2=O)[CH](O)[CH](O)C1=CC=C(O)C(OS([O-])(=O)=O)=C1)[CH](O)CC(N)=O)NC(=O)C1=CC=C(C=C1)C1=NOC(=C1)C1=CC=C(OCCCCC)C=C1)[CH](C)O
Mitotane,ClC(Cl)C(C1=CC=C(Cl)C=C1)C1=C(Cl)C=CC=C1,Hepatobiliary disorders,Human,-3.7781512503836434,Repeated,Oral,"EMA approval document: Assessment Report EMA/CHMP/419286/2013; EMEA/H/C/000521/II/0014, page:18 PDF 825k",https://www.pharmapendium.com/browse/ema/Mitotane/7bc18fcf288cf07b3c8ba3f8938708bd?reference=18,2013.0,ClC(Cl)C(C1=CC=C(Cl)C=C1)C1=C(Cl)C=CC=C1
Nifurtimox,CC1CS(=O)(=O)CCN1\N=C\C1=CC=C(O1)N(=O)=O,Hepatobiliary disorders,Human,-1.0,Repeated,Oral,"FDA approval package document: Approval Package 213464/S-000 Part 11, page:14 PDF 1328k",https://www.pharmapendium.com/browse/fda/Nifurtimox/e9d4eb0685abf6ace1b8ed30e239e58d?reference=14,2020.0,CC1CS(=O)(=O)CCN1\N=C\C1=CC=C(O1)N(=O)=O
Olaparib,FC1=CC=C(CC2=NNC(=O)C3=CC=CC=C23)C=C1C(=O)N1CCN(CC1)C(=O)C1CC1,Hepatobiliary disorders,Human,-2.6020599913279625,Repeated,Oral,"EMA approval document: Assessment Report EMA/CHMP/789139/2014; EMEA/H/C/003726/0000, page:146 PDF 3649k",https://www.pharmapendium.com/browse/ema/Olaparib/4a8bb43cae260418da7bc88978d36d6d?reference=146,2014.0,FC1=CC=C(CC2=NNC(=O)C3=CC=CC=C23)C=C1C(=O)N1CCN(CC1)C(=O)C1CC1
Olodaterol Hydrochloride,COC1=CC=C(CC(C)(C)NC[C@H](O)C2=C3OCC(=O)NC3=CC(O)=C2)C=C1,Hepatobiliary disorders,Human,-1.0,Repeated,Inhalation,"FDA approval package document: Medical/Clinical Review 203108/S-000, page:344 PDF 47237k",https://www.pharmapendium.com/browse/fda/Olodaterol Hydrochloride/68fb24453b3f342f829e3fee17616baa?reference=344,2012.0,COC1=CC=C(CC(C)(C)NC[CH](O)C2=C3OCC(=O)NC3=CC(O)=C2)C=C1
Ozanimod Hydrochloride,CC(C)OC1=C(C=C(C=C1)C1=NC(=NO1)C1=C2CC[C@H](NCCO)C2=CC=C1)C#N,Hepatobiliary disorders,Human,-0.0,Repeated,Oral,"FDA approval package document: Medical/Clinical Review 209899/S-000 Part 03, page:19 PDF 10208k",https://www.pharmapendium.com/browse/fda/Ozanimod Hydrochloride/7164e6e8c274a00edb449ad7de1788ce?reference=19,2019.0,CC(C)OC1=C(C=C(C=C1)C1=NC(=NO1)C1=C2CC[CH](NCCO)C2=CC=C1)C#N
Pioglitazone Hydrochloride,CCC1=CN=C(CCOC2=CC=C(CC3SC(=O)NC3=O)C=C2)C=C1,Hepatobiliary disorders,Human,-1.6532125137753437,Repeated,Oral,"EMA approval document: Scientific Discussion, page:20 PDF 297k",https://www.pharmapendium.com/browse/ema/Pioglitazone Hydrochloride/7e2fe86f1eb5292bd0df81d1b7d3a5de?reference=20,2003.0,CCC1=CN=C(CCOC2=CC=C(CC3SC(=O)NC3=O)C=C2)C=C1
Pitolisant Hydrochloride,ClC1=CC=C(CCCOCCCN2CCCCC2)C=C1,Hepatobiliary disorders,Human,-1.6020599913279623,Repeated,Oral,"FDA approval package document: Medical/Clinical Review 211150/S-000 Part 07, page:3 PDF 643k",https://www.pharmapendium.com/browse/fda/Pitolisant Hydrochloride/6a316bc010e68fb6aa45639b617b9d04?reference=3,2019.0,ClC1=CC=C(CCCOCCCN2CCCCC2)C=C1
Pralsetinib,CO[C@@]1(CC[C@@H](CC1)C1=NC(C)=CC(NC2=NNC(C)=C2)=N1)C(=O)N[C@@H](C)C1=CC=C(N=C1)N1C=C(F)C=N1,Hepatobiliary disorders,Human,-2.6020599913279625,Repeated,Oral,"FDA approval package document: Approval Package 214701/S-000 Part 13, page:2 PDF 2940k",https://www.pharmapendium.com/browse/fda/Pralsetinib/09433c7449b0df8ead2c76561230757d?reference=2,2020.0,CO[C]1(CC[CH](CC1)C1=NC(C)=CC(NC2=NNC(C)=C2)=N1)C(=O)N[CH](C)C1=CC=C(N=C1)N1C=C(F)C=N1
Propranolol Hydrochloride,CC(C)NCC(O)COC1=C2C=CC=CC2=CC=C1,Hepatobiliary disorders,Human,-0.47712125471966244,Repeated,Oral,"EMA approval document: Assessment Report EMA/CHMP/8171/2014; EMEA/H/C/002621/0000, page:60 PDF 1085k",https://www.pharmapendium.com/browse/ema/Propranolol Hydrochloride/f5541888a6562d91f0eb456c3d836fe8?reference=60,2014.0,CC(C)NCC(O)COC1=C2C=CC=CC2=CC=C1
Raltegravir Potassium,CN1C(=O)C([O-])=C(N=C1C(C)(C)NC(=O)C1=NN=C(C)O1)C(=O)NCC1=CC=C(F)C=C1,Hepatobiliary disorders,Human,-2.6020599913279625,Repeated,Oral,"FDA approval package document: Medical/Clinical Review 022145/S-036, page:22 PDF 7089k",https://www.pharmapendium.com/browse/fda/Raltegravir Potassium/497bf54b9e47db14b6028bd72f0e693a?reference=22,2017.0,CN1C(=O)C([O-])=C(N=C1C(C)(C)NC(=O)C1=NN=C(C)O1)C(=O)NCC1=CC=C(F)C=C1
Rifaximin,CO[C@H]1\C=C\O[C@@]2(C)OC3=C(C2=O)C2=C(C(O)=C3C)C(O)=C(NC(=O)\C(C)=C/C=C/[C@H](C)[C@H](O)[C@@H](C)[C@@H](O)[C@@H](C)[C@H](OC(C)=O)[C@@H]1C)C1=C2N=C2C=C(C)C=CN12,Hepatobiliary disorders,Human,-0.3010299956639812,Repeated,Oral,"FDA approval package document: Medical/Clinical Review 022554/S-000 Part 05, page:1 PDF 1639k",https://www.pharmapendium.com/browse/fda/Rifaximin/c7ec7e1a2f6e200d49462097cf294c14?reference=1,2009.0,CO[CH]1\C=C\O[C]2(C)OC3=C(C2=O)C2=C(C(O)=C3C)C(O)=C(NC(=O)\C(C)=C/C=C/[CH](C)[CH](O)[CH](C)[CH](O)[CH](C)[CH](OC(C)=O)[CH]1C)C1=C2N=C2C=C(C)C=CN12
Rilpivirine Hydrochloride,CC1=CC(\C=C\C#N)=CC(C)=C1NC1=CC=NC(NC2=CC=C(C=C2)C#N)=N1,Hepatobiliary disorders,Human,-1.6989700043360187,Repeated,Oral,"FDA approval package document: Clinical Pharmacology and Biopharmaceutics Review 202022/S-000 Part 04, page:232 PDF 6725k",https://www.pharmapendium.com/browse/fda/Rilpivirine Hydrochloride/17ee873567907dca0321567a1dd412dd?reference=232,2010.0,CC1=CC(\C=C\C#N)=CC(C)=C1NC1=CC=NC(NC2=CC=C(C=C2)C#N)=N1
Risedronate Sodium,OC(CC1=CC=CN=C1)(P(O)(O)=O)P(O)([O-])=O,Hepatobiliary disorders,Human,-0.6989700043360189,Repeated,Oral,"FDA approval package document: Medical/Clinical Review 022560/S-000, page:111 PDF 2023k",https://www.pharmapendium.com/browse/fda/Risedronate Sodium/037c9c4f4e5b4f7267ef989494f7dd23?reference=111,2009.0,OC(CC1=CC=CN=C1)(P(O)(O)=O)P(O)([O-])=O
Rivaroxaban,ClC1=CC=C(S1)C(=O)NC[C@H]1CN(C(=O)O1)C1=CC=C(C=C1)N1CCOCC1=O,Hepatobiliary disorders,Human,-1.3010299956639813,Repeated,Oral,"EMA approval document: ANNEX I, page:60 PDF 1522k",https://www.pharmapendium.com/browse/ema/Rivaroxaban/f7df462dd06876f288288ba9d48e87d0?reference=60,2020.0,ClC1=CC=C(S1)C(=O)NC[CH]1CN(C(=O)O1)C1=CC=C(C=C1)N1CCOCC1=O
Rosuvastatin Calcium,CC(C)C1=C(\C=C\[C@@H](O)C[C@@H](O)CC([O-])=O)C(=NC(=N1)N(C)S(C)(=O)=O)C1=CC=C(F)C=C1,Hepatobiliary disorders,Human,-1.6020599913279623,Repeated,Oral,"FDA approval package document: Approval Package 021366/S-010 Part 02, page:39 PDF 7895k",https://www.pharmapendium.com/browse/fda/Rosuvastatin Calcium/7e44b12dc2d51e53badbf45757689a3b?reference=39,2007.0,CC(C)C1=C(\C=C\[CH](O)C[CH](O)CC([O-])=O)C(=NC(=N1)N(C)S(C)(=O)=O)C1=CC=C(F)C=C1
Rotigotine,CCCN(CCC1=CC=CS1)[C@H]1CCC2=C(O)C=CC=C2C1,Hepatobiliary disorders,Human,-1.380211241711606,Repeated,Skin,"FDA approval package document: Approval Package 021829/S-002 Part 03, page:50 PDF 20849k",https://www.pharmapendium.com/browse/fda/Rotigotine/40ae7e590dda6d31a58c18d297f8d629?reference=50,2012.0,CCCN(CCC1=CC=CS1)[CH]1CCC2=C(O)C=CC=C2C1
Selexipag,CC(C)N(CCCCOCC(=O)NS(C)(=O)=O)C1=NC(C2=CC=CC=C2)=C(N=C1)C1=CC=CC=C1,Hepatobiliary disorders,Human,-3.2041199826559246,Repeated,Oral,"FDA approval package document: Medical/Clinical Review 207947/S-000 Part 05, page:5 PDF 601k",https://www.pharmapendium.com/browse/fda/Selexipag/0a014815d9b037d06801f9864d8abfcb?reference=5,2015.0,CC(C)N(CCCCOCC(=O)NS(C)(=O)=O)C1=NC(C2=CC=CC=C2)=C(N=C1)C1=CC=CC=C1
Simeprevir Sodium,[H][C@@]12C[C@]1(NC(=O)[C@]1([H])C[C@H](C[C@@]1([H])C(=O)N(C)CCCC\C=C/2)OC1=CC(=NC2=C(C)C(OC)=CC=C12)C1=NC(=CS1)C(C)C)C(=O)[N-]S(=O)(=O)C1CC1,Hepatobiliary disorders,Human,-2.1760912590556813,Repeated,Oral,"FDA approval package document: Medical/Clinical Review 205123/S-000 Part 10, page:4 PDF 2367k",https://www.pharmapendium.com/browse/fda/Simeprevir Sodium/9a86f96307265241c386c6f03cb2c531?reference=4,2013.0,[H][C]12C[C]1(NC(=O)[C]1([H])C[CH](C[C]1([H])C(=O)N(C)CCCC\C=C/2)OC1=CC(=NC2=C(C)C(OC)=CC=C12)C1=NC(=CS1)C(C)C)C(=O)[N-]S(=O)(=O)C1CC1
Sunitinib,CCN(CC)CCNC(=O)C1=C(C)NC(/C=C2\C(=O)NC3=CC=C(F)C=C23)=C1C,Hepatobiliary disorders,Human,-1.8750612633917,Repeated,Oral,"EMA approval document: ANNEX I, page:15 PDF 705k",https://www.pharmapendium.com/browse/ema/Sunitinib/95d35eea3df7c71029f241d18fa5927a?reference=15,2021.0,CCN(CC)CCNC(=O)C1=C(C)NC(/C=C2\C(=O)NC3=CC=C(F)C=C23)=C1C
Telavancin Hydrochloride,CCCCCCCCCCNCCN[C@@]1(C)C[C@@H](O[C@@H](C)[C@H]1O)O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=C2OC3=C(Cl)C=C(C=C3)[C@@H](O)[C@@H](NC(=O)[C@@H](CC(C)C)NC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@H]3C(=O)N[C@H]4C(=O)N[C@@H]([C@H](O)C5=CC=C(OC1=CC3=C2)C(Cl)=C5)C(=O)N[C@H](C(O)=O)C1=C(C(O)=C(CNCP(O)(O)=O)C(O)=C1)C1=C(O)C=CC4=C1,Hepatobiliary disorders,Human,-1.0,Repeated,Intravenous,"EMA approval document: Assessment Report EMEA/H/C/1240, page:85 PDF 3498k",https://www.pharmapendium.com/browse/ema/Telavancin Hydrochloride/9edf01f3eed420fc7024214f5012390f?reference=85,2011.0,CCCCCCCCCCNCCN[C]1(C)C[CH](O[CH](C)[CH]1O)O[CH]1[CH](O)[CH](O)[CH](CO)O[CH]1OC1=C2OC3=C(Cl)C=C(C=C3)[CH](O)[CH](NC(=O)[CH](CC(C)C)NC)C(=O)N[CH](CC(N)=O)C(=O)N[CH]3C(=O)N[CH]4C(=O)N[CH]([CH](O)C5=CC=C(OC1=CC3=C2)C(Cl)=C5)C(=O)N[CH](C(O)=O)C1=C(C(O)=C(CNCP(O)(O)=O)C(O)=C1)C1=C(O)C=CC4=C1
Telbivudine,CC1=CN([C@@H]2C[C@@H](O)[C@H](CO)O2)C(=O)NC1=O,Hepatobiliary disorders,Human,-3.255272505103306,Repeated,Oral,"EMA approval document: Assessment Report EMEA/H/C/000713/R/0023; EMA/CHMP/295078/2012, page:31 PDF 1244k",https://www.pharmapendium.com/browse/ema/Telbivudine/26bec684eea0144300281c5bae47a7f4?reference=31,2012.0,CC1=CN([CH]2C[CH](O)[CH](CO)O2)C(=O)NC1=O
Teriflunomide,C\C(O)=C(/C#N)C(=O)NC1=CC=C(C=C1)C(F)(F)F,Hepatobiliary disorders,Human,-0.8450980400142568,Repeated,Oral,"FDA approval package document: Medical/Clinical Review 202992/S-000 Part 12, page:8 PDF 11938k",https://www.pharmapendium.com/browse/fda/Teriflunomide/9711c01cf59f491dbbc62266f7c8962f?reference=8,2012.0,C\C(O)=C(/C#N)C(=O)NC1=CC=C(C=C1)C(F)(F)F
Testosterone,[H][C@@]12CCC3=CC(=O)CC[C@]3(C)[C@@]1([H])CC[C@]1(C)[C@@H](O)CC[C@@]21[H],Hepatobiliary disorders,Human,-0.47712125471966244,Repeated,Intranasal,"FDA approval package document: Medical/Clinical Review 205488/S-000 Part 07, page:20 PDF 587k",https://www.pharmapendium.com/browse/fda/Testosterone/008e608a6ec60acc2be6957f29d58ccb?reference=20,2013.0,[H][C]12CCC3=CC(=O)CC[C]3(C)[C]1([H])CC[C]1(C)[CH](O)CC[C]21[H]
Testosterone Undecanoate,[H][C@@]12CCC3=CC(=O)CC[C@]3(C)[C@@]1([H])CC[C@]1(C)[C@H](CC[C@@]21[H])OC(=O)CCCCCCCCCC,Hepatobiliary disorders,Human,-2.3010299956639813,Repeated,Oral,"FDA approval package document: Medical/Clinical Review 206089/S-000 Part 13, page:16 PDF 8447k",https://www.pharmapendium.com/browse/fda/Testosterone Undecanoate/1a40d6da5c21b411d04254527c4ec3f0?reference=16,2014.0,[H][C]12CCC3=CC(=O)CC[C]3(C)[C]1([H])CC[C]1(C)[CH](CC[C]21[H])OC(=O)CCCCCCCCCC
Tiotropium Bromide,[H][C@]12O[C@@]1([H])[C@]1([H])C[C@H](C[C@@]2([H])[N+]1(C)C)OC(=O)C(O)(C1=CC=CS1)C1=CC=CS1,Hepatobiliary disorders,Human,-1.255272505103306,Repeated,Inhalation,"FDA approval package document: Medical/Clinical Review 021936/S-000 Part 02, page:84 PDF 15819k",https://www.pharmapendium.com/browse/fda/Tiotropium Bromide/8d1ee12dc3aff2bfbea47dd903974707?reference=84,2008.0,[H][C]12O[C]1([H])[C]1([H])C[CH](C[C]2([H])[N+]1(C)C)OC(=O)C(O)(C1=CC=CS1)C1=CC=CS1
Tivozanib Hydrochloride,COC1=C(OC)C=C2C(OC3=CC=C(NC(=O)NC4=NOC(C)=C4)C(Cl)=C3)=CC=NC2=C1,Hepatobiliary disorders,Human,-1.5314789170422551,Repeated,Oral,"FDA approval package document: Label 212904/S-001, page:10 PDF 539k",https://www.pharmapendium.com/browse/fda/Tivozanib Hydrochloride/18322356090762875a6c6e34c4deeb4c?reference=10,2021.0,COC1=C(OC)C=C2C(OC3=CC=C(NC(=O)NC4=NOC(C)=C4)C(Cl)=C3)=CC=NC2=C1
Vandetanib,COC1=C(OCC2CCN(C)CC2)C=C2N=CN=C(NC3=CC=C(Br)C=C3F)C2=C1,Hepatobiliary disorders,Human,-2.4771212547196626,Repeated,Oral,"EMA approval document: Assessment Report EMA/128076/2012, page:64 PDF 605k",https://www.pharmapendium.com/browse/ema/Vandetanib/8315ea018b90941332eea8e06dcd3ec3?reference=64,2011.0,COC1=C(OCC2CCN(C)CC2)C=C2N=CN=C(NC3=CC=C(Br)C=C3F)C2=C1
Vilazodone Hydrochloride,NC(=O)C1=CC2=C(O1)C=C(C=C2)N1CCN(CCCCC2=CNC3=CC=C(C=C23)C#N)CC1,Hepatobiliary disorders,Human,-1.6020599913279623,Repeated,Oral,"FDA approval package document: Medical/Clinical Review 022567/S-000 Part 03, page:13 PDF 428k",https://www.pharmapendium.com/browse/fda/Vilazodone Hydrochloride/3dafef44160fd07d9b436517602419ca?reference=13,2010.0,NC(=O)C1=CC2=C(O1)C=C(C=C2)N1CCN(CCCCC2=CNC3=CC=C(C=C23)C#N)CC1
Vildagliptin,[H][C@]12C[C@]3([H])C[C@](O)(C1)C[C@](C2)(C3)NCC(=O)N1CCC[C@@H]1C#N,Hepatobiliary disorders,Human,-1.6989700043360187,Repeated,Oral,"EMA approval document: Assessment Report EMA/CHMP/565928/2012; EMEA/H/C/xxxx/WS/0257, page:31 PDF 889k",https://www.pharmapendium.com/browse/ema/Vildagliptin/86030735672e179fe0622145c47fd5b3?reference=31,2012.0,[H][C]12C[C]3([H])C[C](O)(C1)C[C](C2)(C3)NCC(=O)N1CCC[CH]1C#N
Vismodegib,CS(=O)(=O)C1=CC=C(C(=O)NC2=CC=C(Cl)C(=C2)C2=CC=CC=N2)C(Cl)=C1,Hepatobiliary disorders,Human,-2.1760912590556813,Repeated,Oral,"FDA approval package document: Medical/Clinical Review 203388/S-000 Part 06, page:7 PDF 3099k",https://www.pharmapendium.com/browse/fda/Vismodegib/6c5becf2e60faac7e72d44ae17b7281f?reference=7,2012.0,CS(=O)(=O)C1=CC=C(C(=O)NC2=CC=C(Cl)C(=C2)C2=CC=CC=N2)C(Cl)=C1
